Sangamo Therapeutics, Inc. (SGMO), a leader in genomic medicine, announced on Monday that it will reacquire the development and commercialization rights to giroctocogene fitelparvovec. This investigational gene therapy for adults with moderately severe to severe hemophilia A was being developed in collaboration with Pfizer Inc. (PFE).
This decision comes in the wake of Pfizer's choice to terminate the global collaboration and licensing agreement regarding this product. Sangamo is now proactively evaluating various strategies to continue advancing the giroctocogene fitelparvovec program, including the possibility of aligning with a new collaboration partner.
Pfizer's decision reflects its choice not to move forward with the Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions for giroctocogene fitelparvovec, nor to pursue its commercialization.
Notably, in July 2024, Pfizer announced promising topline results from the Phase 3 AFFINE trial. This trial showed that giroctocogene fitelparvovec successfully achieved its primary and key secondary objectives by outperforming current prophylactic treatments.
Sandy Macrae, CEO of Sangamo Therapeutics, commented on these developments, stating, "Giroctocogene fitelparvovec has shown the potential to be a transformative gene therapy for hemophilia A patients. With the positive results from the Phase 3 AFFINE trial, we are optimistic about its prospects for regulatory approval and eventual commercialization."
The material has been provided by InstaForex Company - www.instaforex.com
RobotFX
Posts
Posts
No comments:
Post a Comment